Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Thursday morning. The brokerage issued a sell rating on the stock.

MBRX has been the topic of a number of other research reports. Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Moleculin Biotech in a research report on Monday, March 3rd.

Moleculin Biotech Stock Down 2.6 %

Shares of Moleculin Biotech stock opened at $1.13 on Thursday. The firm’s 50 day moving average price is $1.42 and its 200-day moving average price is $2.07. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $8.85.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.